Hypera (HYPE3) Q2 2026 earnings summary

Executive summary

• Net revenue grew 8.5% year-over-year to R$2,336.7 million in Q2 2026, driven by 7.6% sell-out growth in pharma retail, outperforming market categories by 1.4 percentage points, with key growth in skincare, CNS, gut health, gastroenterology, cardiology, and dermatology.

• Net income from continuing operations increased 15.0% year-over-year to R$490.0 million, supported by lower financial expenses and strong operational performance.

• Operating cash flow surged 85.0% year-over-year to R$819.2 million, representing 108.5% of EBITDA, reflecting disciplined working capital management and inventory reduction.

• Strategic portfolio expansion included a partnership with Astellas for menopause treatments and the approval of Semavy, entering the GLP-1 analog market.

• New product launches contributed to top-line growth, with innovative entries in GLP-1 and non-hormonal menopause treatment.

Financial highlights

• Gross profit rose 11.5% year-over-year to R$1,443.7 million, with gross margin improving by 1.7 p.p. to 61.8%.

• EBITDA from continuing operations reached R$754.9 million, up 4.1% year-over-year, with a margin of 32.3%.

• Free cash flow after investments was R$637.8 million.

• Net financial expenses decreased 16.9% year-over-year to R$176.7 million, mainly due to reduced net debt.

• Net debt at the end of Q2 2026 was R$5,903.5 million, or 2.1x LTM EBITDA.

Outlook and guidance

• Continued focus on innovation and portfolio expansion, with new product launches and strategic partnerships expected to drive future growth.

• Management reaffirmed its capital optimization plan, targeting R$2.5 billion in incremental operational cash generation by 2028 and R$7.5 billion over 10 years.

• CapEx to remain high through 2026 due to strategic projects, with significant reduction expected after 2027.

• Institutional market performance improving, with new launches and entry into oral oncology expected to drive growth.

• Commitment to shareholder remuneration, evidenced by the approval of R$185.2 million in Interest on Equity.